Journal of Virus Eradication (May 2016)
Prevalence and characterization of NS5A resistance associated variants (RAVs) in patients who relapsed following exposure to NS5A inhibitors
- Guillaume Penaranda,
- Philippe Halfon,
- Caroline Scholtès,
- Sofiane Mohamed,
- Vincent Leroy,
- Marc Bourlière,
- Denis Ouzan,
- Guillaume Pénaranda,
- Hacène Khiri,
- Laura Polverel,
- Fabien Zoulim,
- Marie-Ange Thélu,
- Sylvie Larrat
Affiliations
- Guillaume Penaranda
- European Hospital, Alphabio Laboratory, Marseille, France
- Philippe Halfon
- European Hospital, Alphabio Laboratory, Marseille, France
- Caroline Scholtès
- European Hospital, Alphabio Laboratory, Marseille, France
- Sofiane Mohamed
- European Hospital, Alphabio Laboratory, Marseille, France
- Vincent Leroy
- European Hospital, Alphabio Laboratory, Marseille, France
- Marc Bourlière
- European Hospital, Alphabio Laboratory, Marseille, France
- Denis Ouzan
- European Hospital, Alphabio Laboratory, Marseille, France
- Guillaume Pénaranda
- European Hospital, Alphabio Laboratory, Marseille, France
- Hacène Khiri
- European Hospital, Alphabio Laboratory, Marseille, France
- Laura Polverel
- European Hospital, Alphabio Laboratory, Marseille, France
- Fabien Zoulim
- European Hospital, Alphabio Laboratory, Marseille, France
- Marie-Ange Thélu
- European Hospital, Alphabio Laboratory, Marseille, France
- Sylvie Larrat
- European Hospital, Alphabio Laboratory, Marseille, France
- Journal volume & issue
-
Vol. 2
p. 8
